Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Eur J Dermatol ; 30(1): 24-31, 2020 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-32031529

RESUMEN

BACKGROUND: Cutaneous adverse drug reactions (CADRs) are drug-induced skin reactions with or without systemic involvement, ranging from mild maculopapular exanthema (MPE) to life-threatening severe CADRs (S-CADRs). Due to their unpredictability and severity, early recognition of suspected causative drugs is highly recommended. However, the profile of CADRs remains unknown in China. OBJECTIVES: To assess the clinical profile, predominant causative drugs, and cost associated with CADRs in Shanghai, China. MATERIALS AND METHODS: Clinical records of inpatients admitted with a diagnosis of CADRs to the dermatology ward of Huashan Hospital from January 2007 to December 2016 were retrospectively studied. RESULTS: A total of 1,883 patients (1,231 female and 652 male), admitted with a diagnosis of CADR, were investigated. S-CADRs made up 21.99% of all cases (n=414), and urticaria (27.19%) was the most frequent reaction. Of the patients, 53.43% suffered from multiple drug-induced drug eruptions and the rest (45.83%) from single drug-induced drug eruptions. Overall, antimicrobials (28.85%) was the main drug group involved, and for S-CADRs, this was antiepileptic drugs (36.15%). The total cost for CADRs was RMB23,718,788.83 ($3,588,319.04). Both age and sex were related to admission cost (p=0.005 and p=7.84E-8, respectively). Antimicrobials were the most common treatment causing CADRs. CONCLUSION: The management of CADRs requires considerable medical cost. CADRs are not only a health problem but also a significant financial burden for affected individuals.


Asunto(s)
Antibacterianos/efectos adversos , Anticonvulsivantes/efectos adversos , Erupciones por Medicamentos/economía , Erupciones por Medicamentos/etiología , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Alopurinol/efectos adversos , Analgésicos/efectos adversos , Antipiréticos/efectos adversos , Niño , China , Medicamentos Herbarios Chinos/efectos adversos , Femenino , Supresores de la Gota/efectos adversos , Costos de la Atención en Salud , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Factores Sexuales , Urticaria/inducido químicamente , Adulto Joven
3.
Nutr Cancer ; 68(7): 1083-96, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27472298

RESUMEN

A number of epidemiological studies have explored the association between lycopene or lycopene-rich food intake and the risk of colorectal cancer, but the results of these studies have not been consistent. We conducted a systematic review and meta-analysis of studies published in the PubMed and EMBASE databases to quantitatively assess the association between lycopene consumption and the risk of colorectal cancer. A total of 15 studies were included in the meta-analysis, and the summary relative risk (RR) for highest versus lowest category indicated no significant association between lycopene consumption and the risk of colorectal cancer [RR = 0.94, 95% confidence interval (CI): 0.80-1.10]. However, a significant inverse association was observed between lycopene consumption and the site of cancer in the colon (RR = 0.88, 95% CI: 0.81-0.96). We also found that the incidence of colon cancer and lycopene intake did not exhibit dose-response relationships. The Grades of Recommendations Assessment, Development and Evaluation (GRADE) quality in our study was very low. In conclusion, this meta-analysis indicates that lycopene consumption is not associated with the risk of colorectal cancer. Further research will be needed in this area to provide conclusive evidence.


Asunto(s)
Anticarcinógenos/uso terapéutico , Antioxidantes/uso terapéutico , Carotenoides/uso terapéutico , Neoplasias Colorrectales/prevención & control , Dieta Saludable , Medicina Basada en la Evidencia , Estudios de Casos y Controles , Estudios de Cohortes , Neoplasias Colorrectales/epidemiología , Suplementos Dietéticos , Humanos , Licopeno , Estudios Observacionales como Asunto , Reproducibilidad de los Resultados , Riesgo
4.
Digestion ; 80(3): 148-58, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19713703

RESUMEN

BACKGROUND/OBJECTIVES: Insulin-like growth factor-1 receptor (IGF-1R) displays a key role in tumor transformation and metastasis. It also makes tumor cells more resistant to chemotherapy. The aim of this study was to investigate the correlation between IGF-1R and multidrug resistance-associated protein-1 (MRP-1), and the clinical significance of their expression in gastric carcinoma (GC). METHODS: IGF-1R and MRP-1 expressed in 113 specimens were detected by immunohistochemistry. The correlation between IGF-1R and MRP-1 expression was determined. In addition, the association of their expression with clinicopathological features and survival data of GC was also analyzed. RESULTS: IGF-1R (75.2%) and MRP-1 (69.0%) were frequently expressed in GC. IGF-1R was associated with tumor size, quantity of stroma, depth of wall invasion, lymph node metastasis, TNM stages and differentiation status of GC (p < 0.05). MRP-1 was associated with tumor size, quantity of stroma, lymph node metastasis, distant metastasis and TNM stages (p < 0.05). IGF-1R over-expression positively correlated with MRP-1 over-expression (rp = 0.39, p < 0.01). IGF-1R and MPR-1 over-expression were correlated with poor prognosis of GC (p < 0.01). 102 patients receiving adjuvant FOLFOX-4 chemotherapy who co-expressed IGF-1R/MRP-1 had poor prognosis (p < 0.05). CONCLUSIONS: The levels of co-expression of IGF-1R/MRP-1 in GC may predict the therapeutic effect of chemotherapy and prognosis of GC.


Asunto(s)
Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Receptor IGF Tipo 1/metabolismo , Neoplasias Gástricas/metabolismo , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Resistencia a Múltiples Medicamentos , Resistencia a Antineoplásicos , Femenino , Fluorouracilo/administración & dosificación , Humanos , Inmunohistoquímica , Leucovorina/administración & dosificación , Metástasis Linfática , Masculino , Persona de Mediana Edad , Pronóstico , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/mortalidad , Neoplasias Gástricas/patología , Tasa de Supervivencia
5.
Hunan Yi Ke Da Xue Xue Bao ; 28(2): 117-20, 2003 Apr.
Artículo en Chino | MEDLINE | ID: mdl-12934351

RESUMEN

OBJECTIVES: To study the change of caspase-3 activity on the neoadjuvant chemotherapy-induced apoptosis by hydroxycamptothecin (HCPT) with 5-fluorouracil (5-Fu)/leucovorin (CF) in large-intestinal carcinoma, and to explore its mechanism. METHODS: HCPT 100 mg/dt-5, 5-Fu 500 mg/dt-5 and CF 200 mg/dt-5 were administered intravenously to 20 pre-operation patients. Samples were obtained during the operation. The changes of apoptotic cells and caspase-3 activity in large-intestinal carcinoma were evaluated with the optical microscopy and the colorimeteric assay respectively and were compared with non-chemotherapy group and normal intestinal tissue group. RESULTS: 1. The obvious cell apoptotic change could be observed under the optical microscopy in the neo-adjuvant chemotherapy group; 2. The level of caspase-3 activity was significantly higher in the neo-adjuvant chemotherapy group than in the non-chemotherapy and normal intestinal tissue group(P < 0.05); 3. The change of caspase-3 activity was closely correlated with the tumor differentiation and Dukes stage after the induction of pre-operative chemotherapy. CONCLUSION: HCPT combined with 5-Fu/CF may induce the apoptosis of large-intestinal carcinoma cells and caspase-3 takes part in the apoptotic process. The change of caspase-3 activity was closely correlated with the degree of the tumor differentiation and Dukes stage.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Apoptosis/efectos de los fármacos , Camptotecina/análogos & derivados , Caspasas/metabolismo , Neoplasias del Colon/tratamiento farmacológico , Adenocarcinoma/enzimología , Adenocarcinoma/cirugía , Adulto , Anciano , Camptotecina/administración & dosificación , Caspasa 3 , Quimioterapia Adyuvante , Neoplasias del Colon/enzimología , Neoplasias del Colon/cirugía , Esquema de Medicación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Leucovorina/administración & dosificación , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA